# Person with cancer—histopathological grade, secondary Gleason grade code N

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY4.0 (CC BY4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

# Person with cancer—histopathological grade, secondary Gleason grade code N

# Identifying and definitional attributes

| Metadata item type:   | Data Element   |
|-----------------------|--|
| Short name:           | Secondary Gleason Grade  |
| METEOR identifier:    | 436185   |
| Registration status:  | Health, Standard 14/05/2015  |
| Definition:           | The secondary Gleason grade assigned to a prostate cancer, as represented by a code. |
| Context:              | Only relevant for people with prostate cancer.                                       |
| Data Element Concept: | Person with cancer—histopathological grade   |
| Value Domain:         | Gleason grade code N   |

# Value domain attributes

#### **Representational attributes**

| Representation class: | Code   |         |
|-----------------------|--------|---------|
| Data type:            | Number |         |
| Format:               | Ν      |         |
|                       | Value  | Meaning |
| Permissible values:   | 1      | Grade 1 |
|                       | 2      | Grade 2 |
|                       | 3      | Grade 3 |
|                       | 4      | Grade 4 |
|                       | 5      | Grade 5 |

### Collection and usage attributes

| Guide for use:      | CODE 1 Grade 1  |
|---------------------|---|
|                     | Closely packed small regular glands forming a circumscribed rounded nodule. Not to be used for grading of needle core biopsy specimens.   |
|                     | CODE 2 Grade 2  |
|                     | Glands more loosely arranged; not quite as uniform; fairly circumscribed but may have minimal infiltration at margins. Rarely, if ever, to be used for grading of needle core biopsy specimens. |
|                     | CODE 3 Grade 3  |
|                     | Discrete glandular units/acini with marked variation in size and shape; infiltrates in and amongst benign prostatic tissue.   |
|                     | CODE 4 Grade 4  |
|                     | Fused micro acinar glands; ill-defined glands with poorly formed lumina; large cribriform irregular glands; hypernephroid.  |
|                     | CODE 5 Grade 5  |
|                     | Minimal if any glandular differentiation – solid sheets, cords or single cells.   |
| Collection methods: | To be collected from pathology reports.   |

#### Source and reference attributes

Submitting organisation: Cancer Australia

**Reference documents:** Humphrey PA 2004. Gleason grading and prognostic factors in carcinoma of the prostate. Modern pathology, 17(3): 292-306

Epstein JI, Allsbrook WCJ, Amin MB and Egevad LL 2005. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology 29(9):1228–1242

# Data element attributes

#### **Collection and usage attributes**

| Guide for use:      | The secondary Gleason grade (a specific form of histopathological grade) is the tumour pattern which occupies the second greatest area of tumour based on either sections from a needle core biopsy or radical prostatectomy specimen. This is assigned by a pathologist.  |
|---------------------|--|
|                     | Secondary Gleason grades range from 1 to 5 and are an indicator of how likely it is that a tumour will spread. A low Gleason grade means the cancer tissue is similar to normal prostate tissue and the tumour is less likely to spread; a high Gleason grade means the cancer tissue is very different from normal prostate tissue and the tumour is more likely to spread. The secondary Gleason grade is used in conjunction with the primary Gleason grade to form the <u>Gleason score (or sum)</u> . |
| Collection methods: | To be sought from pathology reports or patient medical records.  |
| Comments:           | A Gleason grade is a prognostic indicator of prostate cancer which may be used to guide treatment and assess whether appropriate treatment protocols have been used.   |

#### Source and reference attributes

Submitting organisation: Cancer Australia

| Reference documents:                          | American College of Surgeons 2011. Facility Oncology Registry Data Standards:<br>Revised for 2011. American College of Surgeons: Chicago.   |
|---|---|
|   | Humphrey PA 2004. Gleason grading and prognostic factors in carcinoma of the prostate. Modern pathology, 17(3), p292-306.   |
|   | Royal College of Pathologists of Australasia 2010. Prostate cancer (radical prostatectomy) structured reporting protocol (1st Ed.). Royal College of Pathologists of Australasia: Sydney. |
| Relational attributes                         |   |
| Related metadata references:                  | Is used in the formation of <u>Person with cancer—histopathological grade, Gleason</u><br>score code N[N]<br><u>Health</u> , Standard 14/05/2015  |
|   | See also <u>Person with cancer—histopathological grade, primary Gleason grade</u><br><u>code N</u><br><u>Health</u> , Standard 14/05/2015   |
| Implementation in Data Set<br>Specifications: | <u>Prostate cancer (clinical) NBPDS</u><br><u>Health</u> , Standard 14/05/2015  |